Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-012536

CHIEF FINANCIAL OFFICER sold 1,000 shares at $22.50 ($22,500)

  • CHIEF FINANCIAL OFFICER acquired 1,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2024-05-03 Exercise or conversion : show line 1 in the form 10b5-1 +1,000 $2.48 $2,480 1,000 D
2024-05-03 Sale : show line 2 in the form 10b5-1 −1,000 $22.50 $22,500 0 D
Open-market sales · 1,000 sh · avg $22.50 · $22,500

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-05-03 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −1,000 221,120 D
Loading xslF345X05/form4-05072024_100528.xml…